EMA Panel Recommends Approval for X4 Pharmaceuticals' WHIM Syndrome Treatment

Key Facts

1The EMA's CHMP adopted a positive opinion recommending the marketing authorization of mavorixafor for WHIM syndrome.

2A final approval decision from the European Commission is anticipated in the second quarter of 2026.

3The drug could become the first and only therapy in the EU for WHIM syndrome, an ultra-rare immune disorder.

The EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the marketing authorization of mavorixafor. Developed by X4 Pharmaceuticals, the drug is designed to treat WHIM syndrome, an ultra-rare primary immunodeficiency. If approved, mavorixafor would become the first and only therapy available for patients with this condition in the European Union. A final decision from the European Commission regarding the marketing authorization is anticipated in the second quarter of 2026. This regulatory milestone represents a significant growth catalyst for X4 Pharmaceuticals (Nasdaq: XFOR) as it targets the European market. The recommendation underscores the clinical potential of the drug to address a critical unmet medical need in the rare disease space.